Compare Amphastar Pharmaceuticals Inc (AMPH) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Williams Companies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Williams Companies Inc trades at $74.88 (market cap $91.75B). The key difference: Williams Companies Inc is far larger — about 111.1× Amphastar Pharmaceuticals Inc's market cap, and Williams Companies Inc pays a 2.8% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WMB | |
|---|---|---|
Market Cap | $826.08M | $91.75B |
Sector | Health | Energy |
52-Week High | $30.81 | $79.40 |
52-Week Low | $16.87 | $56.51 |
Enterprise Value | $1.22B | $121.14B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Williams Companies (WMB) trades at $75.02, down 0.57% on the day, with strong analyst consensus (79% buy ratings) and a $85.58 price target suggesting 14% upside. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust profitability (23.4% net margin) and positive cash flow trends. Recent news highlights WMB's potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure.
WMB presents a compelling investment case with stable fee-based revenue, dividend growth potential, and strategic expansion plans. Key risks include execution of large acquisitions, commodity price volatility exposure, and high debt levels. The current valuation at 32.9x P/E appears elevated but justified by strong earnings growth and sector-leading margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
